SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

ITC moves up on starting clinical trials of nasal spray for COVID-19 prevention

25 Nov 2021 Evaluate

ITC is currently trading at Rs. 231.50, up by 3.60 points or 1.58% from its previous closing of Rs. 227.90 on the BSE.

The scrip opened at Rs. 227.00 and has touched a high and low of Rs. 232.15 and Rs. 225.70 respectively. So far 1306382 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 265.30 on 18-Oct-2021 and a 52 week low of Rs. 192.40 on 01-Dec-2020.

Last one week high and low of the scrip stood at Rs. 240.75 and Rs. 225.70 respectively. The current market cap of the company is Rs. 284092.43 crore.

The Institutions holding in the company stood at 54.53%, while Non-Institutions held 45.47%.

ITC’s Life Sciences and Technology Centre (LSTC) is developing a nasal spray for COVID-19 prevention for which it has initiated clinical trials. Developed by scientists at ITC (LSTC), the company plans to market the nasal spray under the Savlon brand once it gets all the requisite regulatory approvals. The product has the potential to be effective and safe in preventing infection and transmission of COVID-19 along with the existing measures of hygiene recommended by health authorities.

ITC’s LSTC has been at the core of the company’s drive for science led product innovation to support and build its wide range of product portfolio.

ITC has business a interests in cigarettes, hotels, paperboards and specialty papers, packaging, agribusiness,  packaged foods and confectionery, information technology, branded apparel, personal care, stationery, safety matches and other FMCG products.



ITC Share Price

306.80 3.35 (1.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
ITC 306.80
Godfrey Phillips 2207.10
VST Industries 265.10
The Indian Wood Pro. 34.45
NTC Industries 172.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×